Youhong Liu

87 Xiangya Road
Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization.

A Hybrid compound H93 treats prostate cancer by directly binding UHRF1 and promoting protein dimerization.

Journal: Communications chemistry

Published: March 28, 2025

A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.

A mitochondrial outer membrane protein TOMM20 maintains protein stability of androgen receptor and regulates AR transcriptional activity in prostate cancer cells.

Journal: Oncogene

Published: September 22, 2024

SKP2 inhibition activates tumor cell-intrinsic immunity by inducing DNA replication stress and genomic instability.

SKP2 inhibition activates tumor cell-intrinsic immunity by inducing DNA replication stress and genomic instability.

Journal: British journal of cancer

Published: January 24, 2024

A novel COL3A1 variant associated with vascular Ehlers-Danlos syndrome in a patient presents as recurrent pneumothorax with cavities.

A novel COL3A1 variant associated with vascular Ehlers-Danlos syndrome in a patient presents as recurrent pneumothorax with cavities.

Journal: QJM : monthly journal of the Association of Physicians

Published: March 30, 2023

PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability.

PLK1 maintains DNA methylation and cell viability by regulating phosphorylation-dependent UHRF1 protein stability.

Journal: Cell death discovery

Published: November 28, 2022

AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.

AR antagonists develop drug resistance through TOMM20 autophagic degradation-promoted transformation to neuroendocrine prostate cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 26, 2022

UHRF1 promotes spindle assembly and chromosome congression by catalyzing EG5 polyubiquitination.

UHRF1 promotes spindle assembly and chromosome congression by catalyzing EG5 polyubiquitination.

Journal: The Journal of cell biology

Published: October 24, 2022

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer.

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer.

Journal: Oncogenesis

Published: October 03, 2022

Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation.

Diosgenin inhibits prostate cancer progression by inducing UHRF1 protein degradation.

Journal: European journal of pharmacology

Published: September 20, 2022

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells.

Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cells.

Journal: Journal of experimental & clinical cancer research : CR

Published: February 23, 2022

Norcantharidin promotes cancer radiosensitization through Cullin1 neddylation-mediated CDC6 protein degradation.

Norcantharidin promotes cancer radiosensitization through Cullin1 neddylation-mediated CDC6 protein degradation.

Journal: Molecular carcinogenesis

Published: January 20, 2022

USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.

USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 02, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026